scholarly journals Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma

2020 ◽  
Vol 8 (2) ◽  
pp. e001235
Author(s):  
Sattva S Neelapu ◽  
Sherry Adkins ◽  
Stephen M Ansell ◽  
Joshua Brody ◽  
Mitchell S Cairo ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Patient Outcomes ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Healthcare Professionals ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Clinical Implementation ◽  
Non Hodgkin Lymphoma ◽  
Immunotherapy Of Cancer

The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups. The rapid introduction of immunotherapeutic agents into the clinic, however, has presented significant questions regarding optimal treatment scheduling around existing chemotherapy/radiation options, as well as a need for improved understanding of how to properly manage patients and recognize toxicities. To address these challenges, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in lymphoma to develop a clinical practice guideline for the education of healthcare professionals on various aspects of immunotherapeutic treatment. The panel discussed subjects including treatment scheduling, immune-related adverse events (irAEs), and the integration of immunotherapy and stem cell transplant to form recommendations to guide healthcare professionals treating patients with lymphoma.

scholarly journals Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer

2021 ◽  
Vol 9 (7) ◽  
pp. e002552
Author(s):  
Matthew D Galsky ◽  
Arjun V Balar ◽  
Peter C Black ◽  
Matthew T Campbell ◽  
Gail S Dykstra ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Patient Outcomes ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Urothelial Cancer ◽  
Diagnostic Testing ◽  
Care Providers ◽  
Immunotherapy Of Cancer ◽  
Selection Of

A number of immunotherapies have been developed and adopted for the treatment of urothelial cancer (encompassing cancers arising from the bladder, urethra, or renal pelvis). For these immunotherapies to positively impact patient outcomes, optimal selection of agents and treatment scheduling, especially in conjunction with existing treatment paradigms, is paramount. Immunotherapies also warrant specific and unique considerations regarding patient management, emphasizing both the prompt identification and treatment of potential toxicities. In order to address these issues, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in the field of immunotherapy for urothelial cancer. The expert panel developed this clinical practice guideline (CPG) to inform healthcare professionals on important aspects of immunotherapeutic treatment for urothelial cancer, including diagnostic testing, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with urothelial cancer.

2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapya

2018 ◽  
Vol 68 (1) ◽  
pp. 1-4 ◽  
Author(s):  
Anne H Norris ◽  
Nabin K Shrestha ◽  
Genève M Allison ◽  
Sara C Keller ◽  
Kavita P Bhavan ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Infectious Diseases ◽  
Antimicrobial Stewardship ◽  
Antimicrobial Therapy ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Healthcare Professionals ◽  
Outpatient Parenteral Antimicrobial Therapy ◽  
Infusion Catheter

Abstract A panel of experts was convened by the Infectious Diseases Society of America to update the 2004 clinical practice guideline on outpatient parenteral antimicrobial therapy (OPAT) [1]. This guideline is intended to provide insight for healthcare professionals who prescribe and oversee the provision of OPAT. It considers various patient features, infusion catheter issues, monitoring questions, and antimicrobial stewardship concerns. It does not offer recommendations on the treatment of specific infections. The reader is referred to disease- or organism-specific guidelines for such support.

Clinical Practice Guideline Nonadherence and Patient Outcomes in Pediatric Appendicitis

2021 ◽  
Vol 257 ◽  
pp. 135-141
Author(s):  
Dalya M. Ferguson ◽  
Alexandra B. Ferrante ◽  
Hillary A. Orr ◽  
Seyed A. Arshad ◽  
Maile E. Curbo ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Patient Outcomes ◽  
Clinical Practice Guideline ◽  
Practice Guideline

scholarly journals Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

2020 ◽  
Vol 8 (2) ◽  
pp. e001511
Author(s):  
Marcela V Maus ◽  
Sara Alexander ◽  
Michael R Bishop ◽  
Jennifer N Brudno ◽  
Colleen Callahan ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Effector Cell ◽  
Cancer Therapeutics ◽  
Immune Effector Cell ◽  
Cell Therapies ◽  
Immune Effector ◽  
Hematological Cancers ◽  
Immunotherapy Of Cancer

Immune effector cell (IEC) therapies offer durable and sustained remissions in significant numbers of patients with hematological cancers. While these unique immunotherapies have improved outcomes for pediatric and adult patients in a number of disease states, as ‘living drugs,’ their toxicity profiles, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), differ markedly from conventional cancer therapeutics. At the time of article preparation, the US Food and Drug Administration (FDA) has approved tisagenlecleucel, axicabtagene ciloleucel, and brexucabtagene autoleucel, all of which are IEC therapies based on genetically modified T cells engineered to express chimeric antigen receptors (CARs), and additional products are expected to reach marketing authorization soon and to enter clinical development in due course. As IEC therapies, especially CAR T cell therapies, enter more widespread clinical use, there is a need for clear, cohesive recommendations on toxicity management, motivating the Society for Immunotherapy of Cancer (SITC) to convene an expert panel to develop a clinical practice guideline. The panel discussed the recognition and management of common toxicities in the context of IEC treatment, including baseline laboratory parameters for monitoring, timing to onset, and pharmacological interventions, ultimately forming evidence- and consensus-based recommendations to assist medical professionals in decision-making and to improve outcomes for patients.

scholarly journals Improving Understandability of Clinical Practice Guideline Recommendations: a Qualitative Study to Develop a Format for Pediatric Cancer Care

2021 ◽  
Author(s):  
Nancy Santesso ◽  
Melissa Beauchemin ◽  
Paula D. Robinson ◽  
Alexandra M. Walsh ◽  
Aaron J. Sugalski ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Qualitative Study ◽  
Clinical Practice Guideline ◽  
Pediatric Cancer ◽  
Practice Guideline ◽  
Health Care Professionals ◽  
Cancer Care ◽  
Healthcare Professionals ◽  
Evidence Synthesis ◽  
Supporting Evidence

Abstract Background: Features of clinical practice guideline (CPG) recommendations may affect understanding and consequently successful uptake and implementation. We aimed to develop a recommendation format to improve understandability among healthcare professionals involved in pediatric cancer care.Methods: We conducted a multi-center qualitative study of health care professionals at participating pediatric oncology sites. We developed an initial format based on the current literature and used the “think-aloud” technique in multiple rounds of one-on-one cognitive interviews to iteratively improve it. Interviews were conducted until the format was well understood and no new, substantive suggestions for revision were raised. We took a directed (deductive) approach to content analysis of the interview notes to identify concerns related to the understandability of the recommendation. Results: Five investigators interviewed 33 healthcare professionals from multiple disciplines in seven rounds. We identified important factors influencing how to communicate recommendations. Regarding the strength of the recommendation, participants found understanding weak recommendations more challenging than strong. Understanding was improved by using the word ‘conditional’ instead of ‘weak’. Participants believed the inclusion of a rationale section to be very helpful. More information was desirable when a recommendation entailed a practice change. Although participants wanted additional information, they were concerned that there could be too much information. They, therefore, suggested that key words and the studies included in the evidence synthesis be hyperlinked to explanatory data. In the final format, the recommendation strength is clearly indicated in the title, highlighted, and defined within a text box. The rationale for the recommendation is in a column on the left, with supporting evidence on the right. In a bulleted list, the rationale section describes the benefits and harms and additional factors, such as implementation, that were balanced by the CPG developers. Each bullet under the supporting evidence section indicates the level of evidence with an explanation and the supporting studies with hyperlinks when applicable. Conclusions: A well-understood recommendation format to present strong and conditional recommendations was created through an iterative interview process. The format is straightforward, making it easy for organizations and CPG developers to use it to communicate recommendations clearly to intended users.

scholarly journals Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer

2021 ◽  
Vol 9 (8) ◽  
pp. e002597
Author(s):  
Leisha A Emens ◽  
Sylvia Adams ◽  
Ashley Cimino-Mathews ◽  
Mary L Disis ◽  
Margaret E Gatti-Mays ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Practice ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Checkpoint Inhibitors ◽  
Diagnostic Testing ◽  
Progression Free Survival ◽  
The United States ◽  
Care Providers ◽  
Immunotherapy Of Cancer

Breast cancer has historically been a disease for which immunotherapy was largely unavailable. Recently, the use of immune checkpoint inhibitors (ICIs) in combination with chemotherapy for the treatment of advanced/metastatic triple-negative breast cancer (TNBC) has demonstrated efficacy, including longer progression-free survival and increased overall survival in subsets of patients. Based on clinical benefit in randomized trials, ICIs in combination with chemotherapy for the treatment of some patients with advanced/metastatic TNBC have been approved by the United States (US) Food and Drug Administration (FDA), expanding options for patients. Ongoing questions remain, however, about the optimal chemotherapy backbone for immunotherapy, appropriate biomarker-based selection of patients for treatment, the optimal strategy for immunotherapy treatment in earlier stage disease, and potential use in histological subtypes other than TNBC. To provide guidance to the oncology community on these and other important concerns, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). The expert panel drew upon the published literature as well as their clinical experience to develop recommendations for healthcare professionals on these important aspects of immunotherapeutic treatment for breast cancer, including diagnostic testing, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence-based and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with breast cancer.

Sign in / Sign up

Export Citation Format

Share Document